Retatrutide Phase 3 TRIUMPH-1 Results: Key Findings for Researchers

Retatrutide (LY3437943) is a first-in-class triple hormone receptor agonist and one of the most closely watched compounds in current GLP-1-class research — its Phase 3 TRIUMPH program has reported the largest average weight-reduction signal of any incretin-based compound studied to date. This guide consolidates what the published literature shows about retatrutide in one place: how it works, what the trial data has found, what’s been reported about tolerability, how it compares mechanistically to tirzepatide and semaglutide, and where to find research-grade material and related guidance on this site. Use the links below to jump to any section.

What Is Retatrutide

Retatrutide is an investigational peptide that activates three separate hormone receptors at once: the glucagon-like peptide-1 receptor (GLP-1 receptor), the glucose-dependent insulinotropic polypeptide receptor (GIP receptor), and the glucagon receptor (GCGR). Because it engages all three, researchers classify it as a triple agonist — one receptor pathway beyond tirzepatide’s dual GLP-1/GIP mechanism, and two beyond semaglutide’s single-receptor GLP-1 mechanism.

In plain terms, each additional receptor pathway gives researchers another variable to study. GLP-1 receptor activation is associated in the literature with glucose-dependent insulin signaling and satiety-pathway effects. GIP receptor activation is associated with additional effects on lipid handling in adipose tissue. Glucagon receptor activation — unique to retatrutide among the incretin-class compounds most widely studied today — is associated with increased energy expenditure and hepatic lipid metabolism. Researchers point to this combination as the pharmacological rationale for the weight-reduction signal observed in retatrutide’s trial data (see Benefits below).

Retatrutide (Eli Lilly’s internal designation LY3437943) first reported Phase 2 findings in 2023 in the New England Journal of Medicine and has since progressed through a multi-study Phase 3 program under the TRIUMPH name, alongside a type 2 diabetes program (TRANSCEND). As of this writing, retatrutide remains an investigational compound — it is not FDA-approved for human use. Eli Lilly has indicated it plans to complete its chemistry-manufacturing-controls (CMC) package and file a Biologics License Application (BLA) with the FDA in Q1 2027, following July 2026 topline results from the TRIUMPH-2 (type 2 diabetes) and TRIUMPH-3 (severe obesity with established cardiovascular disease) trials. In August 2026, Lilly also confirmed it would begin reviewing individual expanded-access applications from physicians for a narrow group of patients with refractory obesity and serious weight-related complications who cannot enroll in an ongoing trial — a case-by-case pathway that is distinct from, and does not substitute for, FDA approval or routine prescribing.

Portal to Wellness sells retatrutide strictly as a Research Use Only (RUO) product for laboratory and analytical research — not for human or veterinary administration. See the Products section below.

Reported Findings in the Published Literature

The findings summarized below come from Eli Lilly’s pharmaceutical clinical trial program studying the drug product retatrutide in human research subjects. They describe what investigators have reported in specific trial populations — they are not a promise, guarantee, or instruction for individual outcomes, and they are not a claim about the research-grade material sold on this site.

TRIUMPH-1: General Obesity Population

TRIUMPH-1 is a randomized, placebo-controlled Phase 3 trial that enrolled 2,339 adults with obesity (BMI ≥30) or overweight with at least one weight-related comorbidity, without type 2 diabetes. The trial ran 80 weeks and tested 4mg, 9mg, and 12mg weekly subcutaneous doses against placebo. Eli Lilly reported positive topline results on May 21, 2026.

These figures represent average outcomes across the trial population and are not predictive of individual results in any research context.

TRIUMPH-4: Knee Osteoarthritis Substudy

Lilly’s TRIUMPH-4 trial, in participants with obesity/overweight and knee osteoarthritis, reported 28.7% mean weight loss at 68 weeks on the 12mg dose (26.4% at 9mg) versus 2.1% for placebo, alongside a 75.8% reduction in WOMAC knee-pain scores and improved physical-function measures (Eli Lilly investor release).

Sleep Apnea Substudy

A TRIUMPH-1 substudy in participants with obstructive sleep apnea reported a 60.6% reduction in apnea-hypopnea index (AHI), adding a respiratory endpoint to the compound’s Phase 3 research profile alongside the weight-loss and diabetes data above.

Type 2 Diabetes Population: TRANSCEND-T2D-1

A separate Phase 3 trial, TRANSCEND-T2D-1, published in March 2026, examined retatrutide in participants with type 2 diabetes mellitus. At 40 weeks, researchers observed mean weight loss of 16.8% on retatrutide 12mg, alongside roughly a 1.6 percentage-point reduction in A1C reported in later program updates. The attenuated weight-loss signal relative to the non-diabetes population aligns with patterns seen in tirzepatide and semaglutide trials, where baseline metabolic status influences the magnitude of absolute weight change.

Cross-Trial Comparison of Weight-Loss Magnitude

Across published Phase 3 obesity-population data, retatrutide’s TRIUMPH-1 trial produced 28.3% mean weight loss (n=2,339) versus approximately 22.5% for tirzepatide (SURMOUNT program) and 14.9% for semaglutide (STEP program) in comparable populations. These are cross-trial comparisons rather than head-to-head randomized data, so differences in patient population and trial design may account for some of the gap — see the full Comparison section below.

Side Effects: What the Trial Literature Has Reported

Retatrutide was generally described as well tolerated across the TRIUMPH-1 trial. The reported adverse-event profile is consistent with the broader GLP-1 class — primarily gastrointestinal in nature (nausea, vomiting, diarrhea) and most pronounced during dose-escalation periods.

Trial investigators reported that the discontinuation rate due to adverse events at the 12mg dose was 11.3%, compared with 4.9% in the placebo group — a meaningfully higher rate that researchers have flagged as relevant to tolerability analysis. This is higher than discontinuation rates reported in tirzepatide Phase 3 trials at comparable efficacy doses.

The TRIUMPH-4 (knee osteoarthritis) readout introduced a new reported signal: dysesthesia (altered sensation), which investigators described as generally mild and rarely leading to discontinuation.

A limited cardiovascular-events analysis from a later TRIUMPH readout showed numerically more major cardiovascular events (MACE-3: cardiovascular death, heart attack, or stroke) in the retatrutide arm than placebo (27 vs. 23 events; hazard ratio 1.12, 95% CI 0.64–1.96). This difference is not statistically significant and comes from a trial that was not designed or powered to answer a cardiovascular-safety question — researchers have characterized it as a signal to watch in future dedicated outcome trials (Lilly’s TRANSCEND CV program is ongoing), not evidence that retatrutide increases cardiovascular risk.

No long-term (multi-year) human safety dataset for retatrutide has been published as of this writing. Researchers evaluating tolerability should review the primary trial publications directly for full adverse-event tables rather than relying on summary figures.

Mechanism of Action

Retatrutide’s pharmacology is built around unimolecular engagement of three structurally related class-B G-protein-coupled receptors: GLP-1R, GIPR, and GCGR. Unlike a fixed-ratio co-formulation of separate molecules, retatrutide is a single peptide engineered to bind and activate all three receptors, which the published literature describes as a “triple agonist” or “tri-agonist” pharmacophore.

Researchers distinguish the retatrutide mechanism from its comparators as follows:

• GLP-1 receptor agonism — shared by semaglutide, tirzepatide, and retatrutide — is associated with glucose-dependent insulin secretion, delayed gastric emptying, and central satiety signaling.
• GIP receptor agonism — shared by tirzepatide and retatrutide — is studied for its role in adipose-tissue lipid handling. Published pharmacology characterizing tirzepatide describes it as an imbalanced, biased dual agonist favoring GIP-receptor activity, with roughly fivefold weaker affinity at the GLP-1 receptor than native GLP-1 itself; at the GLP-1 receptor it also shows signaling bias favoring cAMP generation over β-arrestin recruitment.
• Glucagon receptor agonism — unique to retatrutide among the three — is hypothesized to contribute additional thermogenesis and hepatic lipid metabolism effects. Researchers investigating the relative contribution of each receptor component point to this pathway as the leading explanation for the weight-reduction signal observed above tirzepatide’s ceiling in cross-trial data.

Retatrutide is studied as a once-weekly subcutaneous injection in the published trial literature, with dose titration used in trial design to manage gastrointestinal tolerability during the early weeks of exposure — consistent with dosing patterns reported for other incretin-class compounds in Phase 2 and Phase 3 programs. This article does not provide administration instructions; see the Research Guides section for where to find general research summaries published on this site.

Open mechanistic questions researchers are actively investigating include: how glucagon-receptor engagement affects energy expenditure independently of weight loss; whether TRIUMPH-1 body-composition substudies (not yet published) will show a more favorable fat-to-lean-mass ratio than reported for GLP-1 mono-agonists; whether the 11.3% high-dose discontinuation rate reflects a threshold effect specific to triple agonism or a dose-escalation-rate artifact; and how efficacy and tolerability will compare against amylin/GLP-1 combinations such as CagriSema once head-to-head data matures.

Comparison: Retatrutide vs. Tirzepatide vs. Semaglutide

Three compounds dominate current metabolic-research conversations: semaglutide, tirzepatide, and retatrutide. They are often grouped together as “GLP-1s,” but at the receptor level they are three genuinely different molecules — a single-receptor agonist, a dual agonist, and a triple agonist. The differences in which receptors each one activates are the throughline for everything else reported below.

• Semaglutide → GLP-1 receptor only (mono-agonist). The most mature published literature of the three and the benchmark every newer molecule is measured against.
• Tirzepatide → GIP + GLP-1 receptors (dual agonist). Large head-to-head pharmaceutical trial data (SURPASS-2) reported superior glucose and weight reductions versus the highest approved dose of semaglutide.
• Retatrutide → GIP + GLP-1 + glucagon receptors (triple agonist). The newest of the three, with the largest reported average weight-loss signal and the least long-term published data.

Note on the third receptor: glucagon-receptor agonism runs in the opposite direction of GLP-1/GIP on blood glucose, but is studied for its role in energy expenditure and lipid metabolism — distinct from the amylin-receptor mechanism used by combinations like CagriSema. Researchers comparing mechanism classes may also want to review our glossary entry on amylin analogues for that adjacent pathway.

For research purposes, the molecule itself is only half of what matters — what’s actually in the vial is the other half. Before trusting any research-compound source, verify a third-party Certificate of Analysis (COA) per batch reporting purity percentage, compound identity, and heavy-metal screening, plus identity confirmation matching the COA to the lot received. See where our own testing stands.

Frequently Asked Questions

What is the core mechanistic difference between retatrutide, tirzepatide, and semaglutide?
Semaglutide is a GLP-1 receptor agonist, tirzepatide is a dual GIP/GLP-1 agonist, and retatrutide is a triple GIP/GLP-1/glucagon agonist — each compound engaging one additional receptor pathway than the last.

What did the TRIUMPH-1 trial find?
TRIUMPH-1, a Phase 3 trial in 2,339 adults with obesity, reported a mean 28.3% body-weight reduction at 80 weeks on the 12mg dose versus 3.9% for placebo. Researchers should check the latest peer-reviewed publication for current figures, as several additional TRIUMPH readouts have since reported.

Is retatrutide FDA-approved?
No. As of this writing it remains investigational. Eli Lilly has indicated it plans to file a Biologics License Application in Q1 2027, following the TRIUMPH-2 and TRIUMPH-3 topline results reported in July 2026.

What side effects has the trial literature reported?
Primarily gastrointestinal effects (nausea, vomiting, diarrhea) consistent with the GLP-1 class, most pronounced during dose escalation. The 12mg-dose discontinuation rate due to adverse events was reported at 11.3%, versus 4.9% for placebo. See the Side Effects section above for the full reported profile.

How does retatrutide compare to tirzepatide in published trial data?
Cross-trial data shows a larger average weight-loss signal for retatrutide (28.3% vs. approximately 22.5% for tirzepatide), though these are cross-trial rather than head-to-head randomized comparisons. See the full Comparison section above.

Does Portal to Wellness sell retatrutide for human use?
No. All retatrutide sold on this site is strictly Research Use Only (RUO) material intended for laboratory and analytical research, not for human or veterinary administration.

Research Guides

Portal to Wellness does not publish dosing instructions, treatment schedules, or administration protocols for human use, and nothing in this article should be read as one. For general information on how the published literature structures GLP-1-class compound research and where retatrutide fits into the broader research landscape discussed on this site, see our GLP-1 & Metabolic Research Guide.

Sources: The Pharmaceutical Journal | Clinical Trials Arena | Parahealth: TRIUMPH Program Results | ClinicalTrials.gov NCT05929066 | Eli Lilly investor release | STAT News, expanded access coverage

All compounds referenced in this article are available for research use only. This article is provided for informational and educational purposes. No therapeutic claims are made or implied.

📚 Part of our GLP-1 & Metabolic Research Guide research guide.